Publications
- Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis2016 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Faculty of Physical Education and Sport
- Influence of IGF1 (insulin-like growth factor 1) signaling pathway to the development of cancer diseases2016 | Faculty of Medicine in Pilsen
- Retreatment with erlotinib of a patient with metastatic NSCLC harboring EGFR mutation: a case report2014 | Faculty of Medicine in Pilsen
- Erlotinib in the treatment of advanced squamous cell NSCLC2013 | Faculty of Medicine in Pilsen, Third Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Second-line treatment of advanced NSCLC: Comparison of efficacy of erlotinib and chemotherapy2013 | Faculty of Medicine in Pilsen
- Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?2024 | Faculty of Medicine in Pilsen
- Concomitant antihypertensive medication and outcome of patients with metastatic castration-resistant prostate cancer receiving enzalutamide or abiraterone acetate2024 | Faculty of Medicine in Pilsen
- Pembrolizumab plus enfortumab vedotin in urothelial cancer2024 | Faculty of Medicine in Pilsen
- Klinická onkologie2023 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine, Second Faculty of Medicine
- Circulating Tumor DNA correlates with Lactate Dehydrogenase, CYFRA 21-1, and CRP levels in patients with advanced NSCLC2023 | Faculty of Medicine in Pilsen, Central Library of Charles University, Faculty of Science
Loading network view...
